At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 131 enrolled
Drug / intervention
LY2428757 +3 moredrug
Likely dose
LY2428757 14 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Proof of Concept Study to Evaluate the Coadministration of TT223 Given Daily and LY2428757 Given Once-Weekly for Four Weeks in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating LY2428757, TT223, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 131 participants across 29 sites in 2 countries.
Detailed Summary
Test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesPuerto Rico, United States
CollaboratorsOPKO Health, Inc.
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedMar 2009
Primary CompletionMay 2010
TodayJul 2026
First PostedMar 2, 2009
Enrollment StartFeb 1, 2009
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.3 years ago
Interventions
LY2428757drug
14 mg subcutaneous injection 1 time a week for 5 weeks
TT223drug
subcutaneous injection once a day for 4 weeks
Placebo for LY2428757drug
subcutaneous injection 1 time a week for 5 weeks
Placebo for TT223drug
subcutaneous injection once a day for 4 weeks